A phase II clinical trial showed saroglitazar significantly ameliorated ALT, liver fat content (LFC), insulin resistance, and atherogenic dyslipidemia in NAFLD/NASH patients [141] (ClinicalTrials.gov Identifier: NCT03061721). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.